ALX Oncology (ALXO) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ALX Oncology (ALXO) has outperformed PepGen (PEPG) over the past year, losing 38.3% versus a loss of 51.1%. PepGen is the larger company by market cap ($164.6 million vs $163.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALXO | PEPG |
|---|---|---|
| Share price | $1.18 | $2.38 |
| Market cap | $163.17M | $164.62M |
| 1-day change | +4.42% | -0.83% |
| YTD return | 0.00% | -63.44% |
| 1-year return | -38.25% | -51.13% |
| 5-year return | -98.08% | — |
| EPS (TTM) | $-1.13 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.66 | $7.80 |
| 52-week low | $1.05 | $1.31 |
| Distance from 52-week high | -55.64% | -69.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +289.83% | +328.15% |
| Average volume | 1.04M | 946.80K |
| Shares outstanding | 138.28M | 69.17M |
| Employees | 48 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALXO has outperformed PEPG by 12.9 percentage points over the past year.
About ALX Oncology
ALXO stock →ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ALXO vs PEPG FAQ
Which is bigger, ALX Oncology or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $164.62M compared with $163.17M for ALX Oncology (ALXO).
Which stock has performed better over the past year, ALXO or PEPG?
ALXO returned -38.25% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are ALX Oncology and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.